124 240

Cited 6 times in

Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma

 Gwak Ho-Shin  ;  Yee Gi Taek  ;  Park Chul-Kee  ;  Kim Jin Wook  ;  Hong Yong-Kil  ;  Kang Seok-Gu  ;  Kim Jeong Hoon  ;  Seol Ho Jun  ;  Jung Tae-Young  ;  Chang Jong Hee  ;  Yoo Heon  ;  Hwang Jeong-Hyun  ;  Kim Se-Hyuk  ;  Park Bong Jin  ;  Hwang Sun-Chul  ;  Kim Min Su  ;  Kim Seon-Hwan  ;  Kim Eun-Young  ;  Kim Ealmaan  ;  Kim Hae Yu  ;  Ko Young-Cho  ;  Yun Hwan Jung  ;  Youn Ji Hye  ;  Kim Juyoung  ;  Lee Byeongil  ;  Lee Seung Hoon 
 Journal of Korean Neurosurgical Society, Vol.54(6) : 489-495, 2013 
Journal Title
 Journal of Korean Neurosurgical Society 
Issue Date
Anaplastic oligoastrocytoma ; Anaplastic oligodendroglioma ; Chemotherapy ; Recurrence ; Temozolomide
Objective : To evaluate the efficacy of temozolomide (TMZ) chemotherapy for recurrent anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA). Methods : A multi-center retrospective trial enrolled seventy-two patients with histologically proven AO/AOA who underwent TMZ chemotherapy for their recurrent tumors from 2006 to 2010. TMZ was administered orally (150 to 200 mg/m2/day) for 5 days per 28 days until unacceptable toxicity occurred or tumor progression was observed. Results : TMZ chemotherapy cycles administered was median 5.3 (range, 1-41). The objective response rate was 24% including 8 cases (11%) of complete response and another 23 patients (32%) were remained as stable disease. Severe side effects (≥grade 3) occurred only in 9 patients (13%). Progression-free survival (PFS) of all patients was a median 8.0 months (95% confidence interval, 6.0-10.0). The time to recurrence of a year or after was a favorable prognostic factor for PFS (p<0.05). Overall survival (OS) was apparently differed by the patient's histology, as AOA patients survived a median OS of 18.0 months while AO patients did not reach median OS at median follow-up of 11.5 months (range 2.7-65 months). Good performance status of Eastern Cooperative Oncology Group 0 and 1 showed prolonged OS (p<0.01). Conclusion : For recurrent AO/AOA after surgery followed by radiation therapy, TMZ could be recommended as a salvage therapy at the estimated efficacy equal to procarbazine, lomustine, and vincristine (PCV) chemotherapy at first relapse. For patients previously treated with PCV, TMZ is a favorable therapeutic option as 2nd line salvage chemotherapy with an acceptable toxicity rate.
Files in This Item:
T201305858.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Seok Gu(강석구) ORCID logo https://orcid.org/0000-0001-5676-2037
Chang, Jong Hee(장종희)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.